tezacaftor drug combination ivacaftor elexacaftor

10/13/2023 - "IMPORTANCE PwCF commonly test positive for pathogenic fungi, and more than 90% of the cystic fibrosis patient population is approved for the modulator treatment, Trikafta. "
10/13/2023 - "The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms."
11/01/2022 - "Eruptive melanocytic naevi following initiation of elexacaftor/ivacaftor/tezacaftor for cystic fibrosis."
01/01/2022 - "Trikafta, currently the leading therapeutic in cystic fibrosis (CF), has demonstrated a real clinical benefit. "
05/01/2021 - "Novel reaction to new cystic fibrosis medication Trikafta."

06/01/2020 - "The entry into the clinic of CFTR modulators such as TRIKAFTA has significantly improved life for ∼90% CF patients carrying one or two F508del mutations but challenges remain for rare CFTR mutations and the management of lung infections @SaraOcana1 https://bit.ly/3aRafQF."
10/13/2023 - "Collectively, these results reveal that Trikafta affects infection-relevant A. "
01/01/2022 - "We utilize existing data for single modulator therapies to extrapolate the potential future of pathogen infection in the era of Trikafta therapy."
09/01/2022 - "The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection."

01/01/2020 - "Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. "

01/01/2020 - "Highlights of our annual review of new approvals and launches on global drug markets include the approval and launch of Trikafta, the most widely applicable treatment to date for cystic fibrosis; approval of the first Ebola vaccine for general (rather than emergency) use; the pilot rollout in three African countries of the world's first malaria vaccine; approval of a new treatment option for multidrug-resistant bacterial infections; and the approval and launch in China of the first new drug to treat Alzheimer's disease in more than a decade. "

12/01/2021 - "Twelve years of progressive Mycobacterium abscessus lung disease in CF-Response to Trikafta."
01/01/2023 - "While the positive effect of Trikafta on cystic fibrosis (CF) pulmonary disease is well established, there is limited data about its effect on bone mineral density (BMD), body composition and exercise capacity. "